Preventing Inhibitor Recurrence Indefinitely

NCT04621916 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Hemophilia A
Immune Tolerance

Interventions

DRUG: FVIII
DRUG: Emicizumab

Sponsor

Children's Hospital Los Angeles

Collaborators

[object Object]